Method for producing a drug delivery system
Inventors
Schneeberger, Achim • Kühne, Klaus • KERSCHBAUMER, Helmut • VASIC, Srdan
Assignees
Laxxon Medical AG • Exentis Knowledge GmbH • Exentis Knowldege GmbH
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.
Core Innovation
The invention provides a method for producing a drug delivery system by sequential screen-printing and curing a base paste and a separate first paste. The first paste comprises a therapeutically effective amount of a first active pharmaceutical ingredient, and both the base paste and the first paste are soluble in body fluids so that the resulting drug delivery system is soluble in body fluids.
In the resulting drug delivery system, the first paste is arranged inhomogeneously in the base paste, including through a three-dimensional arrangement throughout the base paste along three dimensions. The method produces an inhomogeneous arrangement so that the concentration of the first active pharmaceutical ingredient varies throughout the drug delivery system, and a transition from an area with a high concentration to an area with a low concentration is smooth rather than abrupt.
The concentration profile is configured such that, upon application of the drug delivery system, release of the first active pharmaceutical ingredient occurs at a varying rate. The first active pharmaceutical ingredient is an anticancer agent, and the inhomogeneous three-dimensional concentration profile produced by screen-printing and curing is linked to predetermined release behavior characterized by varying release rate.
Claims Coverage
The claim coverage includes one independent claim with three inventive features centered on producing a soluble drug delivery system by screen-printing and curing a base paste and a separate API-containing paste to form a smooth, three-dimensional, inhomogeneous concentration profile that yields a varying release rate for an anticancer agent. Dependent claims refine release-profile and concentration-profile constraints, and optionally add a second API with phasing behavior.
Soluble drug delivery system formed by sequential screen-printing and curing
Screen-printing a base paste, curing the base paste, screen-printing a first paste separate to the base paste, and curing the first paste, wherein the first paste comprises a therapeutically effective amount of a first active pharmaceutical ingredient and the base paste and the first paste are soluble in body fluids such that the resulting drug delivery system is soluble in body fluids.
Three-dimensional inhomogeneous arrangement of the first paste
Screen-printing the pastes such that the first paste is inhomogeneously arranged in the base paste, with the base paste provided as a three-dimensional body and the separate first paste inhomogeneously arranged throughout the base paste along the three dimensions.
Smooth high-to-low API concentration transition with varying-rate release
Screen-printing the pastes such that the concentration of the first active pharmaceutical ingredient varies throughout the drug delivery system, with a smooth transition from an area with a high concentration to an area with a low concentration, and such that upon application the release of the first active pharmaceutical ingredient occurs at a varying rate, wherein the first active pharmaceutical ingredient is an anticancer agent.
Overall, the claim coverage centers on forming a soluble drug delivery system by separately screen-printing and curing an API-containing paste in an inhomogeneous, three-dimensional manner within a base paste, producing a smooth high-to-low concentration transition tied to varying release rate upon application for an anticancer agent.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?